Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // December 12th, 2011 // 8:08 am
Good morning, everyone, and how are you today? We hope the weekend was relaxing and invigorating. Ours was certainly restful. Now, though, the time has come to prepare for all those meetings and deadlines. To cope, yes, we are, indeed, brewing that mandatory cup of stimulation. Monday mornings are always challenging, as you know. We hope you will join us as we dig in for another busy day. To get started, here are a few items of interest. Have a great day and stay in touch…
Abbott Pays $400M To Extend Deal With Reata (Pharma Times)
Onyx Denied Accelerated Review For Cancer Drug (Bloomberg News)
Ariad Blood Cancer Drug Shows Success In Pivotal Study (Bloomberg News)
Gene Therapy Proves Effective In Treating Hemophelia B (Reuters)
FDA Panel Backs J&J’s Birth Control Patch Despite Risks (Associated Press)
UK’s NHS Prescription Data To Be Opened To Public (The Guardian)
India’s Drugmakers Resist Price Controls (Business Standard)
China To Revoke Pharma Licenses For Using Prohibited Chemicals (Xinhua)
Family Appeals Double-Dosed Digitek Ruling (Daily Record)
EDITOR’S NOTE: Please check this post for updates throughout the morning
Coffee pix thx to chichcacha flickr creative commons
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Abbott Laboratories, Ariad Pharmaceutical, Birth Control, Cancer, China, Contraceptives, Digitek, FDA, Gene Therapy, Hemophilia B, JJ, Johnson & Johnson, Multiple Myeloma, Onyx Pharmaceutical, Ortho Evra, Prescribing Data, Prescription Drug Data, Reata, UK